drugset / Trial / NCT01238861
Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of the study is to evaluate the effect of multiple-dose subcutaneous administrations of MEDI-563 on adults with uncontrolled asthma.
Timeline
- Start
- 2010-12
- Primary completion
- 2013-03
- Completion
- 2013-08
Publications
- Results Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, Khatry DB, van der Merwe R, Kolbeck R, Molfino NA, Raible DG. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014 Nov;2(11):879-890. doi: 10.1016/S2213-2600(14)70201-2. Epub 2014 Oct 8.
- Sridhar S, Liu H, Pham TH, Damera G, Newbold P. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Respir Res. 2019 Jan 18;20(1):14. doi: 10.1186/s12931-018-0968-8.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benralizumab | Monoclonal antibody | 2 mg | Subcutaneous |
| Subject | Benralizumab | Monoclonal antibody | 20 mg | Subcutaneous |
| Subject | Benralizumab | Monoclonal antibody | 100 mg | Subcutaneous |